Australia - engelsk - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - epirubicin hydrochloride, quantity: 2 mg/ml - injection, solution - excipient ingredients: sodium chloride; hydrochloric acid; water for injections - farmorubicin has the ability to induce useful responses in a broad spectrum of neoplastic diseases, such as carcinoma of breast, malignant lymphomas, sarcomas of the soft tissues, gastric carcinoma, carcinoma of liver, pancreas, sigmoid rectum, cervico-facial carcinoma, lung carcinoma, ovarian carcinoma and leukemia. high doses of farmorubicin can be used in the treatment of breast cancer. positive results have been obtained with farmorubicin administered intravesically in the treatment of superficial bladder tumors, transitional cells (carcinoma in situ), and in the prophylaxis of recurrences after transurethral resection.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - epirubicin hydrochloride, quantity: 2 mg/ml - injection, solution - excipient ingredients: sodium chloride; hydrochloric acid; water for injections - farmorubicin pfs is recommended for use in the treatment of the following types of cancer: - transitional cell bladder cancer - early-stage, advanced and/or metastatic breast cancer - gastric cancer - palliative chemotherapy for cancer of the oesophago-gastric junction - head and neck cancers - leukaemia - non-small cell lung cancer (nsclc) - small cell lung cancer (sclc) - non-hodgkin lymphomas (nhls), hodgkin lymphoma (hl) - multiple myeloma - ovarian cancer - pancreatic cancer treated with the combined cisplatin, epirubicin, 5-fluorouracil and gemcitabine (pefg) regimen - bowel cancer - soft tissue sarcomas.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - epirubicin hydrochloride, quantity: 2 mg/ml - injection, solution - excipient ingredients: sodium chloride; hydrochloric acid; water for injections - .farmorubicina is used in adults to treat different types of tumour: ? breast cancer; ? malignant lymph node tumours (lymphoma); ? soft tissue tumours (sarcomas); - cancer of the stomach and intestine (sigmoid rectal cancer) ? liver cancer; ? pancreatic cancer; ? cancer of the head or neck (cervical and facial segment) ? lung cancer; ? ovarian cancer; ? blood cancer (leukaemia).

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - epirubicin hydrochloride, quantity: 2 mg/ml - injection, solution - excipient ingredients: sodium chloride; hydrochloric acid; water for injections - farmorubicin can be used alone or in combination with other medicines, in treatment of the following types of cancers: - breast cancer. - soft tissue sarcoma: malignant tumors that can affect the cartilage, muscles, fat, blood vessels, or others. - stomach cancer. - small cell lung cancer (a special type of lung cancer). - advanced ovarian cancer. - early (superficial) tumors of the bladder and as possible prevention of relapses after surgery. ?

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - epirubicin hydrochloride, quantity: 2 mg/ml - injection, solution - excipient ingredients: sodium chloride; hydrochloric acid; water for injections - intravenous farmorubicine as monotherapy has shown an antitumour activity in breast carcinoma, gastric carcinoma and also in soft tissue sarcoma. in addition, objective responses have been observed in a smaller number of patients treated for a certain number of other tumours (pancreatic, ovarian, non-hodgkin's lymphoma). farmorubicine can be included in polychemotherapy regimens because it is less cardiotoxic than doxorubicin. intravesical administration of epirubicin has produced positive results in superficial bladder tumours, both in therapeutic use and prophylactic use after transurethral resection. however, intravesical instillation is contra-indicated in the treatment of an invasive tumour that has penetrated the bladder wall.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - epirubicin hydrochloride, quantity: 2 mg/ml - injection, solution - excipient ingredients: sodium chloride; hydrochloric acid; water for injections - intravenous farmorubicine as monotherapy has shown an antitumour activity in breast carcinoma, gastric carcinoma and also in soft tissue sarcoma. in addition, objective responses have been observed in a smaller number of patients treated for a certain number of other tumours (pancreatic, ovarian, non-hodgkin's lymphoma). farmorubicine can be included in polychemotherapy regimens because it is less cardiotoxic than doxorubicin. intravesical administration of epirubicin has produced positive results in superficial bladder tumours, both in therapeutic use and prophylactic use after transurethral resection. however, intravesical instillation is contra-indicated in the treatment of an invasive tumour that has penetrated the bladder wall.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - epirubicin hydrochloride, quantity: 2 mg/ml - injection, solution - excipient ingredients: sodium chloride; hydrochloric acid; water for injections - indications for chile: farmorubicin has the ability to induce useful responses in a broad spectrum of neoplastic diseases, such as carcinoma of breast, malignant lymphomas, sarcoma of the soft tissues, gastric carcinoma, carcinoma of the liver, pancreas, sigmoid rectum, cervicofacial carcinoma, lung carcinoma, ovarian carcinoma and leukemia. high doses of farmorubicin can be used in the treatment of breast cancer. positive results have been obtained with farmorubicin administered intravesically in the treatment of superficial bladder tumors, transitional cells (carcinoma in situ), and in the prophylaxis of recurrences after transurethral resection. indications for colombia:treatment of aeute leukemias, malignant lymphomas, soft tissue sarcoma, gastric cancer, liver cancer, pancreatic cancer, rectosigmoid (bowel) cancer, head and neck cancer, lung cancer, ovarian cancer.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - epirubicin hydrochloride, quantity: 2 mg/ml - injection, solution - excipient ingredients: sodium chloride; hydrochloric acid; water for injections - ? breast cancer; ? malignant lymph node tumours (lymphoma); ? soft tissue tumours (sarcomas); - cancer of the stomach and intestine (sigmoid rectal cancer) ? liver cancer; ? pancreatic cancer; ? cancer of the head or neck (cervical and facial segment) ? lung cancer; ? ovarian cancer; ? blood cancer (leukaemia). farmorubicina 10 mg/5 ml e 50 mg/25 ml is also administered directly into the bladder (intravesical route), in the treatment of early (superficial) bladder cancer and to prevent bladder cancer relapse after surgery (transurethral resection).

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - epirubicin hydrochloride, quantity: 2 mg/ml - injection, solution - excipient ingredients: sodium chloride; hydrochloric acid; water for injections - epirubicin hydrochloride ? the active substance in farmorubicin ? belongs to a group of active substances known as anthracyclines. these cell-damaging active substances are used to treat cancer. epirubicin is used alone or in combination with other medicines for the treatment of the following types of cancer: ? breast cancer ? stomach cancer ? lung cancer ? ovarian cancer ? prostate cancer ? colon cancer ? soft tissue sarcomas (malignant tumours of the soft tissue such as fatty tissue, muscle tissue or connective tissue) epirubicin is also used intravesically (i.e. administration into the bladder) to treat early (superficial) cancer of the bladder or to prevent the recurrence of bladder cancer following surgery.

Belgia - fransk - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

pfizer sa-nv - chlorhydrate d'epirubicine 50 mg - poudre pour solution injectable - 50 mg - chlorhydrate d'epirubicine 50 mg - epirubicin